newsfilter
← Latest News
PR Newswire·

Keenova Presents a New TERLIVAZ® (terlipressin) Exploratory Analysis at American College of Gastroenterology Annual Meeting

MNK
  • Keenova Therapeutics announced a new presentation on hepatorenal syndrome-acute kidney injury (HRS-AKI) & TERLIVAZ at the American College of Gastroenterology Annual Meeting held October 9-14, 2026.
  • The presentation, scheduled for October 12, details an exploratory analysis of the CONFIRM trial regarding the efficacy & safety of terlipressin in patients ineligible for liver transplant.
  • Nancy Reau, MD, served as the presenting author, highlighting findings that expand clinical evidence for terlipressin use in liver transplant-ineligible patients.
  • TERLIVAZ is the first & only FDA-approved therapy indicated to improve kidney function in adults with HRS-AKI.
  • HRS-AKI is a life-threatening condition marked by rapid kidney function decline, with U.S. inpatient diagnoses rising from 42,930 to 63,381 between 2018 & 2023.
  • TERLIVAZ is contraindicated in patients with serum creatinine levels greater than 5 mg/dL as they are unlikely to experience benefit.
  • A boxed warning highlights the risk of serious or fatal respiratory failure, particularly in patients with volume overload or acute-on-chronic liver failure Grade 3.
  • Treatment requires baseline oxygen saturation assessment, continuous pulse oximetry monitoring, & discontinuation if SpO2 drops below 90%.
  • TERLIVAZ is contraindicated in patients with ongoing coronary, peripheral, or mesenteric ischemia, or those experiencing hypoxia.
  • Adverse reactions occurring in ≥10% of patients include abdominal pain, nausea, respiratory failure, diarrhea, & dyspnea.
  • The drug may cause fetal harm & should be used with caution in pregnant women who are informed of potential risks.
  • TERLIVAZ-related adverse reactions may render patients ineligible for liver transplantation if listed, especially for those with high prioritization (MELD ≥35).
  • Keenova Therapeutics is a U.S.-focused branded therapeutics company headquartered in Dublin, Ireland, with manufacturing facilities in Louisiana, New Jersey, New York, Pennsylvania, & Wisconsin.